Search results for "Outbreak"
showing 10 items of 812 documents
¿ Será mejor la salud pública tras la COVID-19?
2021
Reducing mortality from 2019-nCoV: host-directed therapies should be an option
2020
An epidemiological study exploring a possible impact of treatment with ACE inhibitors or angiotensin receptor blockers on ACE2 plasma concentrations
2020
Out-of-hospital cardiac arrest during the COVID-19 era: The importance to fight against fear
2021
Cardiac safety and potential efficacy: two reasons for considering minocycline in place of azithromycin in COVID-19 management
2020
Currently, there is no effective therapy for COVID-19, and several approaches are under investigation. Nevertheless, some drugs are used off-label despite the absence of clear data on their effectiveness. Among these, hydroxychloroquine suppresses SARS-CoV-2 replication in vitro,1 and clinical trials are ongoing to evaluate its use as an anti-COVID-19 agent. To date, the FDA and EMA allow its use only in hospitalized patients with severe COVID-19 or in those at high risk, in cases where other trials are not feasible. According to a small non-randomized study, hydroxychloroquine’s efficacy might be enhanced by azithromycin, as the combination of these two drugs appeared to accelerate viral c…
Differential impact of COVID-related lockdown on mental health in Germany.
2021
The war against coronavirus disease 19 through the eyes of cancer physician: An Italian and Indian young medical oncologist's perspective
2020
These are unprecedented times, we are living in with an outbreak of a novel coronavirus, also known as severe acute respiratory syndrome coronavirus 2 (CoV-2), or CoV Disease 19 (COVID-19). By April 20th, as per the World Health Organization Data, COVID-19 as a pandemic has caused 2,407,414 cases, and 165,073 confirmed deaths in 213 different countries worldwide. Elderly patients and those with comorbid illnesses with COVID-19 infection have poor outcomes. Cancer patients are immunosuppressed, and at an increased risk of COVID-19 infection and have worse outcomes as compared to the general population. The mortality rate of COVID-19 among oncology patients is about 20%.[1] Young oncologists …
Letter of Reply to “Response to: COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinant…
2021
To the Editors, We thank Drs. R. Mungmunpuntipantip and V. Wiwanitkit1 for their comment on our recently published article, “COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Italian IBD Patients’ Association”.
Is Persistent Thick Copious Mucus a Long-Term Symptom of COVID-19?
2020
Introduction The typical clinical picture of COVID-19 is gradually becoming clearer, both in the acute phase and in the long-term. However, new symptoms are gradually being identified. We describe a long-term symptom that has not yet been reported. Case description A 49-year-old man consulted for persistent asthenia. The general practitioner found a fever (39.2°C), and COVID-19 was confirmed by the polymerase chain reaction test. Further symptoms appeared, notably thick, white, painless tracheal hypersecretion for 3 months before diminishing, without disappearing. Conclusion Non-inflammatory tracheal hypersecretion, not yet reported in COVID-19, may be an additional long-term symptom. The h…